H. Lundbeck Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Charl van Zyl

Chief executive officer

kr.39.6m

Total compensation

CEO salary percentage	6.8%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	1.7yrs
Board average tenure	3.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Charl van Zyl's remuneration changed compared to H. Lundbeck's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	kr.40m	kr.3m	kr.2b

Compensation vs Market: Charl's total compensation ($USD5.69M) is above average for companies of similar size in the UK market ($USD2.58M).

Compensation vs Earnings: Insufficient data to compare Charl's compensation with company performance.

CEO

Charl van Zyl (56 yo)

less than a year

Tenure

kr.39,600,000

Compensation

Mr. Charl van Zyl served as Executive Vice President Neurology Solutions & Head of EU/International at UCB SA since February 2020 until June 2023. He serves as President and Chief Executive Officer of H. L...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Charl van Zyl	President & CEO	less than a year	kr.39.60m	no data
Joerg Hornstein	CFO & Executive VP of Corporate Functions	1.7yrs	kr.10.90m	0.0023% DKK 729.5k
Lars Bang	Executive Vice President of Product Development & Supply	5.3yrs	kr.10.10m	0.038% DKK 12.3m
Per Luthman	Executive Vice President of Research & Development	5.3yrs	kr.11.30m	0.014% DKK 4.5m
Tarek Samad	Senior VP & Head of Research	2.9yrs	no data	no data
Palle Olesen	Chief Specialist & VP of Investor Relations	no data	no data	no data
Tine Hansen	Senior Vice President of Corporate Communications & Public Affairs	less than a year	no data	no data
Dianne Holto	Executive Vice President of People & Organization	no data	no data	no data
Ole Chrintz	Senior Vice President of International Markets	no data	no data	no data
Rupert Sandbrink	Senior VP & Head of Clinical Development	2.3yrs	no data	no data
Bjorn Mogensen	Senior Vice President of Group Finance	1.7yrs	no data	no data
Jose Molinuevo	VP & Head of Experimental Medicine	no data	no data	no data

1.7yrs

Average Tenure

59yo

Average Age

Experienced Management: 0ND5's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Lars Rasmussen	Independent Chairman	11.3yrs	kr.1.70m	0.010% DKK 3.2m
Lene Skole-Sorensen	Deputy Chairman	9.3yrs	kr.1.20m	0.0062% DKK 2.0m
Jeffrey Berkowitz	Independent Director	6.1yrs	kr.1.20m	no data
Lars Holmqvist	Director	9.3yrs	kr.600.00k	0.0076% DKK 2.4m
Jakob Riis	Director	1.1yrs	kr.450.00k	0.0055% DKK 1.8m
Ilse Wenzel	Independent Director	3.1yrs	kr.70.00k	no data
Santiago Arroyo	Independent Director	3.1yrs	kr.1.00m	no data
Camilla Andersson	Employee Representative Director	2.1yrs	kr.400.00k	0.00010% DKK 32.1k
Dorte Clausen	Employee Representative Director	2.1yrs	kr.400.00k	0.00011% DKK 35.3k
Hossein Armandi	Employee Representative Director	2.1yrs	kr.400.00k	no data
Lasse Skibsbye	Employee Representative Director	2.1yrs	kr.400.00k	no data

3.1yrs

Average Tenure

57yo

Average Age

Experienced Board: 0ND5's board of directors are considered experienced (3.1 years average tenure).

H. Lundbeck Management

Management criteria checks 1/4

Key information

Recent management updates

H. Lundbeck A/S Announces Management Appointments

Key Executive recently bought kr.751k worth of stock

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

Recent updates

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

Upcoming dividend of kr.0.70 per share

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

Key Executive recently bought kr.751k worth of stock

Dividend increased to kr.0.70

Full year 2023 earnings released: EPS: kr.2.31 (vs kr.1.93 in FY 2022)

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

H. Lundbeck A/S(CPSE:LUN) dropped from OMX Nordic All-Share Index

H. Lundbeck A/S Common Stock to Be Deleted from OTC Equity

First quarter 2022 earnings released: EPS: kr.2.07 (vs kr.3.13 in 1Q 2021)

H. Lundbeck A/S Provides Earnings Guidance for the Year 2022

Less than half of directors are independent

H. Lundbeck A/S Completes Global Phase Iv, Randomized, Comparative Study Exploring the Role of Vortioxetine

H. Lundbeck A/S Appoints Joergornstein as Member of Lundbeck's Executive Management

Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTI

Less than half of directors are independent

Upcoming dividend of kr.2.00 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

H. Lundbeck A/S Proposes Dividend for the Year 2021

EU Commission Approves Vyepti[®] (Eptinezumab) for the Preventive Treatment of Migraine in Adults

Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients Ages 13-17

Third quarter 2021 earnings released: EPS kr.1.62 (vs kr.2.38 in 3Q 2020)

Second quarter 2021 earnings released: EPS kr.1.90 (vs kr.2.93 in 2Q 2020)

First quarter 2021 earnings released: EPS kr.3.13 (vs kr.0.76 in 1Q 2020)

H. Lundbeck A/S Provides Revenue Guidance for the Full Year of Fiscal 2021

H. Lundbeck A/S Announces New Study Finds That Vortioxetine Helps Patients with MDD and Comorbid Generalized Anxiety Disorder

Independent Director has left the company

H. Lundbeck A/S Appoints Tarek Samad as Head of Research, Effective on May 1, 2021

Upcoming Dividend of kr.2.50 Per Share

H. Lundbeck A/S Announces Resignation of Henrik Andersen from Board

Full year 2020 earnings released: EPS kr.7.95 (vs kr.13.42 in FY 2019)

Revenue misses expectations

New 90-day high: kr.239

New 90-day high: kr.215

Rigshospitalet and Lundbeck Announce Partnership to Find New Ways to Treat Brain Diseases

Lundbeck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Eptinezumab for the Prevention of Migraine

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2020

H. Lundbeck A/S Revises Earnings Guidance for the Year 2020

Revenue beats expectations

Third quarter 2020 earnings released: EPS kr.2.38

New 90-day low: kr.177

New 90-day low: kr.196

OVATION Pharmaceuticals, Inc. acquired Buronil from H. Lundbeck A/S.

H. Lundbeck A/S Presents Positive Data from the Complete Study with Vortioxetine

New 90-day low - kr.208

Earnings released

New 90-day low - ø231

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age